Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 0.61 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.61 |
| ▸ | STS | P08842 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | ESR1 | P03372 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.61 |
| ▸ | SHBG | P04278 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | PGR | P06401 | 1/20 | 0.61 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | AR | P10275 | 1/20 | 0.61 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | SNCA | P37840 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Almestrone SCHEMBL1657631 | 0.97 | CYP19A1 (0.65) | CYP19A1HSD17B1STSLMNAESR1 | |
| Almestrone SCHEMBL12364346 | 0.97 | CYP19A1 (0.65) | CYP19A1HSD17B1STSLMNAESR1 | |
| Almestrone SCHEMBL12364585 | 0.97 | CYP19A1 (0.65) | CYP19A1HSD17B1STSLMNAESR1 | |
| Almestrone SCHEMBL5983577 | 0.97 | CYP19A1 (0.65) | CYP19A1HSD17B1STSLMNAESR1 | |
| Almestrone SCHEMBL13216952 | 0.97 | CYP19A1 (0.65) | CYP19A1HSD17B1STSLMNAESR1 | |
| Almestrone SCHEMBL8089798 | 0.97 | CYP19A1 (0.65) | CYP19A1HSD17B1STSLMNAESR1 | |
| SCHEMBL6535977 | 0.87 | HSD17B1 (0.67) | CYP19A1HSD17B1STSLMNAESR1 | |
| SCHEMBL12364241 | 0.87 | HSD17B1 (0.67) | CYP19A1HSD17B1STSLMNAESR1 | |
| SCHEMBL14421698 | 0.87 | HSD17B1 (0.67) | CYP19A1HSD17B1STSLMNAESR1 | |
| SCHEMBL2244884 | 0.87 | HSD17B1 (0.67) | CYP19A1HSD17B1STSLMNAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351587-B2 | Method of making and using 7α, 11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-07-16 | — | — | US | disclosed |
| US-20110195942-A1 | METHOD OF MAKING AND USING 7ALPHA, 11BETA-DIMETHYL-17BETA-HYDROXYESTR-4-EN-3-ONE 17-UNDECANOATE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN | 2011-08-11 | — | — | US | disclosed |
| US-20090023695-A1 | METHOD OF MAKING AND USING 7alpha,11beta-DIMETHYL-17beta-HYDROXYESTR-4-EN-3-ONE 17-UNDECANOATE | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH | 2009-01-22 | — | — | US | disclosed |
| US-7196074-B2 | Methods of making, using and pharmaceutical formulations comprising 7α, 11β-dimethyl-17β-hydroxyestra-4, 14-dien-3-one and 17 esters thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1272196-B1 | METHODS OF MAKING THE 4-N-BUTYLCYCLOHEXANOIC AND THE UNDECANOIC ACID ESTERS OF (7 ALPHA,11 BETA)-DIMETHYL-17 BETA-HYDROXY-4-ESTREN-3-ONE AND THEIR MEDICAL USE | US GOV HEALTH & HUMAN SERV (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1379253-B1 | METHODS OF MAKING AND PHARMACEUTICAL FORMULATIONS COMPRISING 7ALPHA,11BETA-DIMETHYL-17BETA-HYDROXYESTRA-4, 14-DIEN-3-ONE AND 17 ESTERS THEREOF | US GOV HEALTH & HUMAN SERV (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050130944-A1 | Method of making and using 7alpha,11beta-dimethyl-17beta-hydroxyestr-4-en-3-one 17-undecanoate | GOVERNMENT OF THE USA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-06-16 | — | — | US | disclosed |
| EP-1379253-A1 | METHODS OF MAKING AND PHARMACEUTICAL FORMULATIONS COMPRISING 7ALPHA,11BETA-DIMETHYL-17BETA-HYDROXYESTRA-4, 14-DIEN-3-ONE AND 17 ESTERS THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030130243-A1 | Methods of making, using and pharmaceutical formulations comprising 7alpha, 11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one and 17 esters thereof and 17 esters of 7alpha-methyl-17beta-hydroxyestra-4,14-dien-3-one | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, | 2003-07-10 | — | — | US | disclosed |
| WO-2003045398-A1 | METHODS OF MAKING AND PHARMACEUTICAL FORMULATIONS COMPRISING 7ALPHA, 11BETA-DIMETHY-17BETA-HYDROXYESTRA-4, 14-DIEN-3-ONE AND 17 ESTERS THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20030069215-A1 | Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, | 2003-04-10 | — | — | US | disclosed |
| EP-1272196-A2 | METHODS OF MAKING THE 4-N-BUTYLCYCLOHEXANOIC AND THE UNDECANOIC ACID ESTERS OF (7 ALPHA,11 BETA)-DIMETHYL-17 BETA-HYDROXY-4-ESTREN-3-ONE AND THEIR MEDICAL USE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001074839-A2 | METHODS OF MAKING THE 4-N-BUTYLCYCLOHEXANOIC AND THE UNDECANOIC ACID ESTERS OF (7 ALPHA, 11 BETA)-DIMETHYL-17 BETA-HYDROXY-4-ESTREN-3-ONE AND THEIR MEDICAL USE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-0356454-B1 | CYCLIC HYDROCARBONS WITH AN AMINOALKYL SIDECHAIN | THE UPJOHN COMPANY (US) | 1992-06-17 | — | — | EP | disclosed |
| US-5001234-A | Cyclic hydrocarbons with an aminoalkyl sidechain | THE UPJOHN COMPANY (US) | 1991-03-19 | — | — | US | disclosed |
| EP-0356454-A1 | CYCLIC HYDROCARBONS WITH AN AMINOALKYL SIDECHAIN. | UPJOHN CO (US) | 1990-03-07 | — | — | EP | disclosed |
| WO-1988008002-A1 | CYCLIC HYDROCARBONS WITH AN AMINOALKYL SIDECHAIN | THE UPJOHN COMPANY (US) | 1988-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023695-A1 | METHOD OF MAKING AND USING 7alpha,11beta-DIMETHYL-17beta-HYDROXYESTR-4-EN-3-ONE 17-UNDECANOATE | HSD17B11, HSD17B13, HSD3B1 | CYP19A1 8/4885HSD17B1 11/4885STS 175/4885 |
| US-20030130243-A1 | Methods of making, using and pharmaceutical formulations comprising 7alpha, 11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one and 17 esters thereof and 17 esters of 7alpha-methyl-17beta-hydroxyestra-4,14-dien-3-one | HSD17B11, CYP19A1, HSD17B7 | CYP19A1 2/4885HSD17B1 7/4885STS 474/4885 |
| US-20110195942-A1 | METHOD OF MAKING AND USING 7ALPHA, 11BETA-DIMETHYL-17BETA-HYDROXYESTR-4-EN-3-ONE 17-UNDECANOATE | HSD17B11, HSD17B13, HSD3B1 | CYP19A1 8/4885HSD17B1 11/4885STS 175/4885 |
| US-20050130944-A1 | Method of making and using 7alpha,11beta-dimethyl-17beta-hydroxyestr-4-en-3-one 17-undecanoate | HSD17B11, HSD17B13, HSD3B1 | CYP19A1 5/4885HSD17B1 8/4885STS 369/4885 |
| US-10351587-B2 | Method of making and using 7α, 11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate | HSD17B11, HSD17B13, CYP19A1 | CYP19A1 3/4885HSD17B1 12/4885STS 164/4885 |
| US-20030069215-A1 | Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate | HSD17B11, CYP19A1, SHBG | CYP19A1 2/4885HSD17B1 8/4885STS 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.